TN2013000491A1 - Amylin peptides and derivatives and uses thereof - Google Patents
Amylin peptides and derivatives and uses thereofInfo
- Publication number
- TN2013000491A1 TN2013000491A1 TNP2013000491A TN2013000491A TN2013000491A1 TN 2013000491 A1 TN2013000491 A1 TN 2013000491A1 TN P2013000491 A TNP2013000491 A TN P2013000491A TN 2013000491 A TN2013000491 A TN 2013000491A TN 2013000491 A1 TN2013000491 A1 TN 2013000491A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methods
- diabetes
- syndrome
- treatment
- type
- Prior art date
Links
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 title 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000008279 Dumping Syndrome Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 208000032395 Post gastric surgery syndrome Diseases 0.000 abstract 1
- 206010049416 Short-bowel syndrome Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000004104 gestational diabetes Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489781P | 2011-05-25 | 2011-05-25 | |
| PCT/US2012/039431 WO2012162542A1 (en) | 2011-05-25 | 2012-05-24 | Amylin peptides and derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000491A1 true TN2013000491A1 (en) | 2015-03-30 |
Family
ID=47217749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000491A TN2013000491A1 (en) | 2011-05-25 | 2013-11-22 | Amylin peptides and derivatives and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20140221287A1 (https=) |
| EP (1) | EP2714067A1 (https=) |
| JP (1) | JP2014516049A (https=) |
| KR (1) | KR20140045433A (https=) |
| CN (1) | CN103826655A (https=) |
| BR (1) | BR112013030067A2 (https=) |
| CA (1) | CA2837104A1 (https=) |
| CL (1) | CL2013003377A1 (https=) |
| CO (1) | CO6821894A2 (https=) |
| EA (1) | EA201391763A1 (https=) |
| IL (1) | IL229449A0 (https=) |
| MX (1) | MX2013013802A (https=) |
| PH (1) | PH12013502385A1 (https=) |
| SG (1) | SG194998A1 (https=) |
| TN (1) | TN2013000491A1 (https=) |
| WO (1) | WO2012162542A1 (https=) |
| ZA (1) | ZA201309679B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2682147C (en) | 2007-03-30 | 2017-08-08 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| CN106687474A (zh) * | 2014-09-04 | 2017-05-17 | 诺和诺德股份有限公司 | 新型胰淀素和降钙素受体激动剂 |
| CN104327162A (zh) * | 2014-09-28 | 2015-02-04 | 苏州普罗达生物科技有限公司 | 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用 |
| SMT202100388T1 (it) | 2014-10-24 | 2021-09-14 | Bristol Myers Squibb Co | Polipeptidi fgf-21 modificati e loro usi |
| WO2018144671A1 (en) * | 2017-02-01 | 2018-08-09 | The Research Foundation For The State University Of New York | Mutant islet amyloid polypeptides with improved solubility and methods for using the same |
| CA3097812A1 (en) * | 2018-04-25 | 2019-10-31 | Janssen Pharmaceutica Nv | Thioether cyclic peptide amylin receptor modulators |
| KR20210124179A (ko) | 2018-11-02 | 2021-10-14 | 베이징 브이디제이바이오 컴퍼니 리미티드 | 변형된 ctla4 및 이의 사용 방법 |
| EP3930757A1 (en) | 2019-03-01 | 2022-01-05 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| CN110467666A (zh) * | 2019-09-17 | 2019-11-19 | 湖北强耀生物科技有限公司 | 一种新型胰岛淀粉样多肽的合成方法 |
| TW202400632A (zh) | 2021-03-03 | 2024-01-01 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| EP4429704A4 (en) | 2021-11-10 | 2025-11-05 | I2O Therapeutics Inc | IONIC LIQUID COMPOSITIONS |
| JP2025517031A (ja) | 2022-05-27 | 2025-05-30 | ハンチョウ サイウィンド バイオサイエンスィズ カンパニー リミテッド | ヒトアミリン類似体、その誘導体およびその使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2385878C2 (ru) * | 2004-02-11 | 2010-04-10 | Амилин Фармасьютикалз, Инк. | Пептид, обладающий свойствами амилина (варианты), и его применение (варианты) |
| BRPI0606992A2 (pt) * | 2005-02-11 | 2009-07-28 | Amylin Pharmaceuticals Inc | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis |
| JP5252435B2 (ja) * | 2006-03-15 | 2013-07-31 | ノボ・ノルデイスク・エー／エス | アミリン誘導体 |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2036539A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| MX2010005317A (es) * | 2007-11-20 | 2010-06-02 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
-
2012
- 2012-05-24 CA CA2837104A patent/CA2837104A1/en not_active Abandoned
- 2012-05-24 EA EA201391763A patent/EA201391763A1/ru unknown
- 2012-05-24 KR KR1020137033991A patent/KR20140045433A/ko not_active Withdrawn
- 2012-05-24 PH PH1/2013/502385A patent/PH12013502385A1/en unknown
- 2012-05-24 JP JP2014512115A patent/JP2014516049A/ja not_active Withdrawn
- 2012-05-24 WO PCT/US2012/039431 patent/WO2012162542A1/en not_active Ceased
- 2012-05-24 US US14/119,574 patent/US20140221287A1/en not_active Abandoned
- 2012-05-24 MX MX2013013802A patent/MX2013013802A/es not_active Application Discontinuation
- 2012-05-24 EP EP12789229.7A patent/EP2714067A1/en not_active Withdrawn
- 2012-05-24 SG SG2013084892A patent/SG194998A1/en unknown
- 2012-05-24 CN CN201280036795.0A patent/CN103826655A/zh active Pending
- 2012-05-24 BR BR112013030067A patent/BR112013030067A2/pt not_active IP Right Cessation
-
2013
- 2013-11-14 IL IL229449A patent/IL229449A0/en unknown
- 2013-11-22 TN TNP2013000491A patent/TN2013000491A1/fr unknown
- 2013-11-25 CL CL2013003377A patent/CL2013003377A1/es unknown
- 2013-12-19 CO CO13296527A patent/CO6821894A2/es not_active Application Discontinuation
- 2013-12-20 ZA ZA2013/09679A patent/ZA201309679B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140221287A1 (en) | 2014-08-07 |
| ZA201309679B (en) | 2016-10-26 |
| KR20140045433A (ko) | 2014-04-16 |
| BR112013030067A2 (pt) | 2016-11-29 |
| EP2714067A1 (en) | 2014-04-09 |
| WO2012162542A1 (en) | 2012-11-29 |
| SG194998A1 (en) | 2013-12-30 |
| CN103826655A (zh) | 2014-05-28 |
| MX2013013802A (es) | 2014-04-25 |
| EA201391763A1 (ru) | 2014-04-30 |
| CO6821894A2 (es) | 2013-12-31 |
| IL229449A0 (en) | 2014-01-30 |
| JP2014516049A (ja) | 2014-07-07 |
| NZ618526A (en) | 2015-09-25 |
| CA2837104A1 (en) | 2012-11-29 |
| PH12013502385A1 (en) | 2014-01-13 |
| CL2013003377A1 (es) | 2014-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2013000491A1 (en) | Amylin peptides and derivatives and uses thereof | |
| WO2013059336A8 (en) | Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties | |
| PH12018501119A1 (en) | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof | |
| HK1213483A1 (zh) | Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂 | |
| MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
| JP2014511863A5 (https=) | ||
| NZ593314A (en) | Dual variable domain immunoglobulins and uses thereof | |
| GEP20176629B (en) | Glucagon/glp-1 receptor co-agonists | |
| HK1207097A1 (en) | Fusion proteins for treating a metabolic syndrome | |
| MX2011013903A (es) | Polipeptidos quimericos y usos de los mismos. | |
| MX2010004450A (es) | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. | |
| EA033405B1 (ru) | Изолированное антитело, которое индуцирует опосредованную фактором роста фибробластов 21 (fgf21) передачу сигнала | |
| EP2121057A4 (en) | POLYMERIZATION WITH PRECIPITATION OF PROTEINS FOR ELUTION IN A PHYSIOLOGICAL SOLUTION | |
| WO2012142604A3 (en) | Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9 | |
| BRPI1010613A2 (pt) | peptídeo cílico, composição farmacêutica, e, métodos para tratar uma doença, distúrbio e/ou condição, e para reduzir a ingestão de alimento, peso corporal e/ou ganho de peso corporal. | |
| WO2007112069A3 (en) | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases | |
| WO2010132389A3 (en) | Methods for treating cancers and diseases associated with 4-1bb (cd137) expression | |
| LT2013018A (lt) | Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus | |
| EP2579876A4 (en) | THERAPEUTIC TREATMENT OF METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDICT | |
| NZ602317A (en) | Stabilized alpha-galactosidase and uses thereof | |
| EP2646032A4 (en) | THERAPEUTIC TREATMENT OF METABOLIC SYNDROME AND TYPE 2 DIABETES, ADIPOSITAS OR PREDICTES | |
| MX2009008243A (es) | Uso de un inhibidor de trpm5 para regular la insulina y la liberacion de glp-1. | |
| PH12015501157B1 (en) | Nutritional composition for promoting satiety | |
| AU2010353685A8 (en) | Novel glucagon like peptide analogs, composition, and method of use | |
| NO20090958L (no) | Behandling av revmatismesykdom med langsom frigivelse av glukokortikoid |